Arrowhead (ARWR) Rated Buy on Metabolic Pipeline Potential

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) ranks among the most profitable biotech stocks to buy now. Following comments on Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)’s obesity and metabolic illness initiatives, TD Cowen reiterated its Buy rating on March 26. The firm pointed out that Wave Life Sciences published more data from Arrowhead’s ARO-INHBE program, demonstrating that, despite the higher dosage, monotherapy WVE-007 produced weight and fat reduction measures that fell short of investor expectations.

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) stated that research is being done to provide hypotheses regarding the optimal locations for INHBE and ALK7 inhibition. In order to further assess this prospect, the company expanded the INHBE studies in response to promising signals in patients with Type 2 diabetes and in combination with tirzepatide, following data disclosed in January.

According to TD Cowen, these methods are most likely to be used in maintenance and supplementary settings, or in other specific indications such as MASH and Type 2 diabetes. The firm stated that it anticipates more information in the latter part of the year, including closely watched sHTG data in the third quarter.

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) develops medicines for the treatment of intractable diseases in the US. Its pipeline primarily includes Plozasiran, Zodasiran, ARO-DIMER-PA, and ARO-PNPLA3.

While we acknowledge the risk and potential of ARWR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ARWR and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.